Cardiovascular Implications of COVID-19
A special issue of Hearts (ISSN 2673-3846).
Deadline for manuscript submissions: closed (1 October 2020) | Viewed by 373
Special Issue Editor
Special Issue Information
Coronavirus disease-2019 (COVID-19), an infectious disease caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2), is the cause of a rapidly evolving global pandemic that has impacted more than two million people worldwide so far. Recent studies indicate that the invasion of the respiratory tract occurs through the angiotensin converting enzyme 2 (ACE2) receptor. Interestingly, ACE2 receptors are highly expressed by the heart, and are involved in cardiac function mediated by the renin-angiotensin system as well as in the development of systemic hypertension (HTN) and diabetes mellitus. Clinical manifestations of COVID-19 are dominated by respiratory symptoms including fever, cough, and shortness of breath, with potential development into severe pneumonia. In a subset of patients, the disease can cause severe cardiovascular (CV) complications such as acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism. In addition, patients with pre-existing CV disease, diabetes mellitus, HTN, or congestive heart failure might have an increased risk of death. Therefore, understanding the mechanisms involved in CV injury caused by SARS-CoV-2 is paramount for the development of effective treatments in patients with cardiac disease.
The aim of this Special Issue of Hearts is to incorporate the latest findings related to the impact of SARS-CoV-2 on the CV system, the outcomes of patients with established CV disease, and the development of successful protocols to improve patient care. We invite researchers from around the world to submit high-quality basic and clinical research (original articles, reviews, and case reports) that provides new insights into (i) the clinical features and outcomes of COVID-19 patients with pre-existing CV diseases and/or acquired CV complications, (ii) the underlying mechanisms of SARS-CoV-2 on CV pathophysiology, (iii) pharmacological approaches to treat COVID-19 patients with CV complications and the potential cardiovascular side effects of such therapies, and (iv) the newly implemented cardiac-related guidelines developed in cardiology wards in the setting of the COVID-19 crisis regarding procedural cardiology preparedness and specific protocols for the management of CV disease patients, especially those patients with both acute myocardial infarction and COVID-19 disease.
This special issue will follow a quality-driven fast-track submission process in order to collect relevant contributions for managing the current COVID-19 crisis. At the same time, MDPI will cover the Article Processing Charges (APC) of all COVID-19 research submitted to this Special Issue.
Dr. Enrique J. Gallego-Colon
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hearts is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiovascular disease
- COVID-19
- SARS-CoV-2
- pneumonia
- angiotensin converting enzyme
- hypertension
- heart failure
- clinical and basic research
- cardiovascular outcomes
- pharmacological interventions
- COVID-19 cardiac protocols
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
